Gilead Sciences

Update in progress

GILD (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines to address unmet medical needs worldwide. It markets HIV therapies (Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo) and hepatitis/viral treatments (Epclusa, Livdelzi, Vemlidy). It also offers Tecartus and Yescarta CAR-T therapies, Trodelvy, AmBisome, and Veklury for COVID-19. Headquartered in Foster City, CA, it pursues numerous collaborations.

Company score

Sentiment: 1.82; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.16; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 1.70; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.35; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.48; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 1.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive